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An emerging ﬁeld of research is starting to examine the association of infectious pathogens with type 2 diabetes mellitus (T2DM).
An understudied parasite of interest is Toxoplasma gondii. Globally, very few studies have been conducted to investigate this
association. Additionally, very little data exists on the prevalence of T. gondii in the general Australian population. Our group
sought to determine the prevalence, association, and risk factors between T. gondii infection and T2DM from a representative
Australian human population. Through a cross-sectional, age- and gender-matched case-control study, 150 subjects with T2DM
together with 150 control subjects from the Busselton Health Study cohort were investigated. Sera samples were tested for the
presence of anti-T. gondii IgG and IgM antibodies using enzyme-linked immunosorbent assays. Survey-derived data were also
analyzed to evaluate associated risk factors. The IgG seroprevalence was found to be 62% and 66% for the T2DM and control
groups, respectively (OR : 0:84; p = 0:471). IgM antibodies were detected in 5% of the T2DM patients and in 10% of the
controls (OR = 0:51; p = 0:135). There were no signiﬁcant diﬀerences between male and female IgG seroprevalence rates for
both groups (OR : 0:88, 0.80; p = 0:723). The IgG seropositivity rate increased signiﬁcantly in T2DM patients aged 45-84 years
in comparison to those aged 18-44 years (p < 0:05), but this was not observed in the control subjects. No risk factors were
associated with T. gondii seropositivity in both groups. The ﬁrst Australian study of its kind found T. gondii infection in
Western Australia to be highly prevalent. The results also showed that there is no serological evidence of an association between
T. gondii infection and T2DM in the studied subjects. Australian health authorities should focus on raising awareness of
toxoplasma infection and target T. gondii transmission control. Further studies are needed to clarify the role of T. gondii in T2DM.

1. Introduction
Diabetes in Australia has reached an epidemic level with an
estimated 6% (1.2 million) of the adult population aged 18
years and over living with the condition [1, 2]. Diabetes is
also the sixth leading cause of death in Australia, responsible
for 10% of all deaths [3]. The majority (86%) of Australian diabetics have type 2 diabetes mellitus (T2DM) with 172 new

cases being diagnosed each day [3]. In fact, diabetes is becoming more common with the rate of prevalence more than doubling from 1.5% to 4.7% between 1989-1990 and 2015-2016
[4]. If the incidence of diabetes continues to grow at the present rates, there will be 2.5-3 million people with diabetes in
Australia by 2025 growing to 3.5 million by 2030 [4].
In 2016, 1.6 million deaths were caused by diabetes
worldwide [5]. This is mainly due to the increase in the

2
numbers of people with T2DM as a result of the increase in
life expectancy, genetic predisposition, physical inactivity,
dietary changes, the obesity epidemic, and the decreased
mortality rates in diabetic individuals [1]. However, there
may also be additional unidentiﬁed novel risk factors, such
as subclinical inﬂammation caused by infectious agents, that
contribute to this rising prevalence of T2DM [6]. In this
regard, an emerging ﬁeld of research is beginning to investigate the potential of infectious and environmental pathogens
to cause low-grade inﬂammation that may facilitate the risk
and development of various metabolic conditions, including
diabetes and obesity.
Toxoplasma gondii (T. gondii) has been identiﬁed as
pathogen of potential interest in this ﬁeld. Considered one
of the most successful human parasites [7], the Centers for
Disease Control and Prevention has prioritisedT. gondii as
one of the top “Five Neglected Parasitic Infections” due to
the severity of illness, high incidence, and potential for prevention [8]. Humans acquire T. gondii infection by the ingestion of food, water, or soil contaminated by oocysts from the
deﬁnitive hosts, cats; consumption of raw/undercooked meat
and sausages which contains bradyzoites; or vertical transmission of tachyzoites by transfusion, transplantation, or
ingestion of raw milk [9, 10]. It has also been hypothesized
that T. gondii may be transmitted via sexual contact [9].
The global prevalence rates of this parasite are phenomenal
with ﬁgures ranging from 15 to 85% depending on social
habits, climate condition, hygienic standards, and geographical regions [11].
Infection can be present with various nonspeciﬁc signs and
symptoms, but most are similar to general ﬂu-like indicators
[12]. In all infections, speciﬁc antibodies to this parasite
remain detectable in the serum throughout the life of the host
[10]. Toxoplasma gondii can infect and replicate in any nucleated host cells, leading to the production of various inﬂammatory markers via the innate acute inﬂammatory responses
and antigen-speciﬁc adaptive immunity. This facilitates a state
of chronic inﬂammation at various anatomical sites in the
host [13, 14]. Several reports have linked chronic T. gondii
infection to several autoimmune disorders such as thyroid
disease, systemic sclerosis, rheumatoid arthritis, and inﬂammatory bowel syndrome with several studies demonstrating
a positive correlation between T. gondii infection and numerous neurological disorders and cancers [10–12, 15, 16].
However, T. gondii infection in individuals with T2DM
has received little recognition, and human studies investigating T. gondii infection in T2DM subjects are scarce. Moreover, there is very limited information on the prevalence,
incidence, and epidemiology of the disease in the general
Australian human population—perhaps because T. gondii
infection is not a notiﬁable disease in Australia and most T.
gondii infections are asymptomatic. The few previous studies
have reported prevalence rates amongst pregnant woman
throughout Australia between 23 and 35% [17–20]. Toxoplasma gondii latent infection has great potential as a novel
target for T2DM intervention and may pave a path for a
new ﬁeld of study, “Toxoplasmic Type 2 Diabetes” [21, 22].
The objectives of this study were to (1) investigate the
possible serological relationship between T. gondii and
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T2DM and (2) identify risk factors for T. gondii infection.
We undertook the ﬁrst age- and gender-matched casecontrol study in Australia by utilizing sera and crosssectional data (respiratory and chest conditions, various
disease states, anthropometric measurements, and laboratory
biochemical and haematological parameters) collected from
a community-dwelling cohort of adults attending the 20052007 Busselton Health Survey in Western Australia.

2. Materials and Methods
The present study describes samples and data collected from
the residents of the inner-regional local government electoral
boundary of the City of Busselton, Western Australia, a centre for farming, vineyards, timber, tourism, and mineral
sands industries. A cross-sectional general population health
survey (Busselton Health Study, BHS) was conducted between
2005 and 2007 with participants recruited from the compulsory electoral role. This survey was conducted by the Busselton
Population Medical Research Institute (BPMRI), a prominent biobank. Details on recruitment and study protocols
from this survey are described in Musk et al. [23]. Ethical
approval for the current analyses was obtained from the
Edith Cowan University Human Research Ethics Committee
(Project Number 16090).
2.1. Study Design. The design of the present study was a casecontrol study in which the seroprevalence of T. gondii in subjects with T2DM (n = 150) was measured and compared to
age- and gender-matched controls (non-T2DM, n = 150).
Clinical and demographic parameters were also investigated
for possible risk factor association. Sera were analyzed for
the presence of IgG and IgM antibodies against T. gondii
using commercially available qualitative ELISA methods
(Demeditec Diagnostics GmbH, Germany). These in-vitro
diagnostic assays have been designed for the qualitative
determination of speciﬁc IgG and IgM antibodies against
T. gondii in serum and plasma, and have claimed clinical
sensitivities and speciﬁcities of 99% and 98%, respectively,
for the IgG assay, and 99% and 100%, respectively, for the
IgM assay.
2.2. Criteria for Selection of Participants. Participants with
T2DM were deﬁned as cases. T2DM was classiﬁed according
to the 1999 World Health Organization (WHO) Criteria
(fasting plasma glucose greater than or equal to 7.0 mmol/L
and/or 2-hour plasma glucose greater than or equal to
11.1 mmol/L) [24]. Healthy participants were deﬁned as controls by reference to the following criteria: (1) did not have a
documented medical diagnosis of diabetes, (2) were not taking any glucose-lowering medications, and (3) have fasting
and 2-hour glucose values below the diagnostic thresholds
for diabetes. In addition, subjects were screened for history
of treatment with psychoactive medication and were
excluded because of the previously reported and established
associations between positive T. gondii serology and numerous forms of mental illnesses [15, 16].
2.3. Sample and Data Collection. The present study utilized
20 μL of serum aliquoted from banked samples (stored at
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-80°C) that have been previously collected from study participants aged 18-80 years attending the 2005-2007 BHS. During this survey, each participant completed a standard selfadministered questionnaire that obtained information on
respiratory and chest conditions and various disease states
and underwent a range of clinical tests including anthropometric, respiratory, and cardiovascular measurements. Each
participant had a blood sample collected from the cubital
fossa in 10 mL red top clot, 2 mL purple top EDTA (ethylenediaminetetraacetic acid), and 2 mL grey top FlOx (ﬂuoride/oxalate) vacutainer tubes (BD Biosciences, Franklin
Lakes, New Jersey, USA) for laboratory biochemical and haematological analyses which were conducted by PathWest
Laboratory Medicine-QEII Medical Centre, Nedlands, Western Australia. The serum for the present study was aliquoted
and stored at -80°C until used.
2.4. Sample Integrity and Laboratory Analysis. To minimize
false positive or false negative results, lipemic, haemolysed,
icteric, or turbid (bacterially contaminated) samples were
excluded. Test samples were diluted 1 : 101 with ready-touse sample diluent (5 μL serum + 500 μL sample diluent).
The total volume of serum required from each subject to perform the IgG and IgM ELISAs was 20 μL (5 μL for IgG
ELISA, 5 μL for IgM ELISA, and 10 μL for repeat testing in
the event of an equivocal result). The case and control sera
were tested for anti-T. gondii IgG and anti-T. gondii IgM
antibodies using the Demeditec Diagnostics DETOX01
(IgG ELISA) and DETOX03 (IgM ELISA) kits according to
the manufacturers’ instructions. Brieﬂy, these assays have
been designed for the qualitative evaluation of speciﬁc IgG
and IgM antibodies against toxoplasma in serum. The analysis was performed double-blind to avoid result bias. Samples
from the female, male, T2DM, and control groups were randomly mixed, and the analyst performing the analysis was
not aware of the source of samples. Then, 100 μL of the
diluted (1 : 101) sample and the ready-to-use calibrators
(IgG [IU/mL]; A, 0; B, 10; C, 40; D, 100; E, 250; IgM
[U/mL]; A, 1; B, 10; C, 30; D, 120) were pipetted into each test
well (coated with T. gondii strain RH antigens, isolated from
infected mice, common to both the IgG and IgM assays) leaving one well empty for the substrate blank. The plate was covered and incubated for 60 minutes at room temperature. The
wells were then washed three times with 300 μL of diluted
washing solution using a Bio-Plex Pro II Microplate Wash
Station (Bio-Rad Laboratories, Berkeley, California). Subsequently, 100 μL of ready-to-use conjugate was added into
each well except the substrate blank well. The plate was covered and incubated at room temperature for 30 minutes. This
was followed by another washing procedure as outlined
above, after which 100 μL of the ready-to-use substrate was
pipetted into each well including the substrate blank well. A
ﬁnal incubation phase for 20 minutes at room temperature
in the dark was performed before terminating the substrate
reaction with the addition of 100 μL of the ready-to-use stop
solution into each well. The plate was then mixed and the
wiped in preparation for reading. This was performed using
a FLUOstar Omega microplate reader (BMG Labtech, Oﬀenburg, Germany) at an absorption of 450 nm. A standard
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curve was generated by plotting the mean absorbance at
450 nm for each standard concentration (x-axis) against the
target antibody concentration (y-axis).
2.5. Qualitative Serology Interpretation. Results were determined qualitatively by comparing the calculated absorptions
for each sample serum with the value for the cutoﬀ calibrators (IgG, 10 IU/mL; IgM, 10 U/mL). Values higher than
the cutoﬀs (IgG, 10 IU/mL; IgM, 10 U/mL) were considered
positive, values less than the cutoﬀs were considered negative, while values falling within a grayzone of ±20% of
the cutoﬀ values were considered equivocal and retested
once.
2.6. Statistical Analyses. Statistical calculations justifying the
sample sizes were performed using G∗Power V3.1.9.2
(Heinrich Heine University Düsseldorf, Germany). The following values were used: power of 95%; a 1 : 1 proportion of
cases and controls; and a reference seroprevalence of 50%
for the T2DM group and 30% for controls. Thus, a minimum
sample size of 139 cases and 139 controls was obtained and
rounded up to 150 subjects per group. Basic descriptive statistics including counts, means, standard deviations, and percentages were calculated for the control and T2DM groups
and their respective gender- and age- subgroups. Age was
divided into seven age groups: 18–34, 35–44, 45–54, 55–64,
65–74, 75–84, and 85 years and older. Seroprevalence rates
(%) of T. gondii including the odds ratios (OR) and corresponding 95% conﬁdence intervals (95% CI) were calculated.
The Fisher’s exact test was used to evaluate the seroprevalence values between case and control subjects with respect
to categorical variables to determine possible risk factor associations. For continuous quantitative variables (laboratory
and anthropometric data), the normality of the data distribution was assessed using the Shapiro-Wilk test, Q-Q (quantilequantile) plots, and skewness and kurtosis values. As the
laboratory and anthropometric data were normally distributed, the parametric independent sample Student’s t-test
was used to compare the selected parameters between the
study groups. Correlation was assessed using the Pearson
correlation coeﬃcient with p value and heat maps was generated to display the interrelationships between the laboratory
and anthropometric data within each study group. Probability values were calculated on the basis of two-tailed tests. For
all analyses, a p value less than 0.05 was considered statistically signiﬁcant. Data were analyzed using the Statistical
Package for Social Sciences (IBM® SPSS® Statistics version
25.0, Armonk, New York, USA).

3. Results
In this study, the case (n = 150) and control (n = 150) cohorts
were matched for age, gender, and age group distribution.
The mean age of the T2DM and control groups was 59:2 ±
15:1 and 58:4 ± 15:7 years, respectively. The mean duration
of T2DM was 6.8 years. Most of patients were in the 55–64
and 65-74 (n = 64) age groups, followed by the 45-54
(n = 62), 35-44, and 75-84 (n = 42) age groups. The basic
descriptive and biometric statistics are summarized in
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Table 1: Basic descriptive and biometric statistics for the study cohort comparing the case (T2DM subjects) and control (non-T2DM healthy
subjects) groups at baseline including age group stratiﬁcation. BHS, Western Australia.
T2DM
(n = 150)

Control
(n = 150)

p

T2DM M
(n = 75)

Control M
(n = 75)

p

T2DM F
(n = 75)

Control F
(n = 75)

p

Average age (years)

59:2 ± 15:1

58:7 ± 15:8

N.S

63:9 ± 13:5

63:5 ± 14:5

N.S

54:6 ± 15:2

54:0 ± 15:8

N.S

Height (cm)

168:1 ± 9:1

168:4 ± 9:3

N.S

174:5 ± 6:7

173:9 ± 7:7

N.S

161:8 ± 6:5

163:0 ± 7:5

N.S

80:1 ± 20:5

68:6 ± 12:2

96:2 ± 16:7

83:3 ± 10:7

30:5 ± 7:4

25:9 ± 4:9

7:2 ± 6:8

—

Parameter

Weight (kg)

85:0 ± 18:5

77:2 ± 15:6

Waist (cm)

99:7 ± 14:8

91:3 ± 13:2

BMI (kg/m2)

30:0 ± 6:0

27:1 ± 4:5

Diabetes duration (years)

6:8 ± 5:8

—

∗∗
∗∗

90:0 ± 14:4

85:8 ± 13:8

104:6 ± 11:2

99:5 ± 10:2

29:5 ± 4:1

28:4 ± 3:8

6:4 ± 4:6

—

∗∗

—

∗∗
∗∗
∗∗

—

∗∗
∗∗
∗∗

Values are shown as mean ± standard deviation. M: male subjects; F: female subjects; n: number of subjects; cm: centimeter; kg: kilogram; BMI: body mass
index; kg/m2: kilogram force per square meter. Level of signiﬁcance as estimated by the independent samples Student’s t-test: N.S: not signiﬁcant; ∗ p < 0:05;
∗∗
p < 0:01.

Table 1. As expected, T2DM subjects had signiﬁcantly higher
weight, waist, and BMI measurements when compared to the
controls. The remainder of the baseline characteristics of the
study groups were not signiﬁcantly diﬀerent (p > 0:05).
3.1. Toxoplasma gondii, T2DM, and Associated Factors. From
the 150 subjects with T2DM, 93 (62.0%) were found to be
seropositive for anti-T. gondii IgG antibodies in comparison
to 99 (66.0%) of the 150 healthy control subjects. The diﬀerence between the two groups was not signiﬁcant (OR : 0:84;
p = 0:470). Anti-T. gondii IgM antibodies were found in 8
(5.0%) of the T2DM patients and in 15 (10.0%) of the control
subjects. Again, the diﬀerence was not signiﬁcant between
the two groups (OR = 0:51; p = 0:129) (Table 2).
Regarding the impact of gender, our results showed similar seroprevalence rates of T. gondii IgG antibodies between
the female and male subjects belonging to the T2DM and
control groups. However, there was a signiﬁcant diﬀerence
in the seroprevalence rate of T. gondii IgM antibodies
between the female T2DM group compared with the female
controls (4.0% and 17.3%, respectively; OR : 0:20; p = 0:008).
This was not observed within the male groups (Table 2).
Anti-T. gondii IgG seropositivity increased with age at
the rates of 0.97% and 0.57%, per year of age, for the
T2DM and control groups, respectively (Figure 1). In the
T2DM group, the 75-84 age group had the highest seropositivity rate at 76.2% (p = 0:011), followed by the 55-64 age
group (75.0%; p = 0:009), the 65-74 age group (71.9%;
p = 0:014), and the 45-54 age group (64.5%; p = 0:037),
whilst the lowest seropositivity of 22.2% was observed
in the 18-34 age group. In contrast, in the control subjects,
no signiﬁcant relationship between increasing age and
increasing percentage of seropositivity for anti-T. gondii
IgG antibodies was observed. IgM was exuded from this
and further analyses due to the low number of seropositive
subjects.
A positive correlation was found between the duration of
T2DM and rate of T. gondii infection in that T2DM subjects
infected with T. gondii had been living with T2DM for longer
(average of 7.6 years, p = 0:044) and were older (average of
63.2 years old, p < 0:001) than their non-T. gondii-infected

T2DM counterparts whom would have been living with
T2DM for a shorter period (average of 5.6 years) and were
younger (average of 52.8 years old). Likewise, for the control
group, a similar trend was observed with infected subjects having a higher average age than the uninfected subjects (average
of 60.9 and 54.5, respectively, p = 0:019) (Table 3).
Regarding pet ownership as a risk factor associated with
T. gondii infection, univariate analysis showed that owning
a cat, dog, and/or other pet was not signiﬁcantly associated
with T. gondii infection. However, subjects with T2DM were
less likely than their matched controls to own a cat
(OR = 0:57, p = 0:140) or other pet (OR = 0:87, p = 0:721)
while the controls reported a higher rate of dog ownership
(OR = 1:32, p = 0:344) when compared to the T2DM subjects. In addition, univariate analysis showed that body
mass index (BMI) among the selected disease states and
lifestyle factors (asthma, arthritis, bronchitis, cancer,
eczema, food allergies, hay fever, other chest conditions,
pleurisy, pneumonia, and sinusitis) were not identiﬁed as
risk factors associated with T. gondii infection (Table 2).
3.2. Laboratory and Anthropometric Analysis. Findings from
the laboratory and anthropometric studies are summarized
in Table 4. As expected, weight, BMI, and waist circumference measurements were signiﬁcantly higher in subjects with
T2DM in comparison to the control subjects (p < 0:01).
Results from laboratory investigations showed that elevated
white cell count (p = 0:016), lymphocyte count (p = 0:020),
neutrophil count (p = 0:039), glucose (p < 0:01), insulin
(p < 0:01), and triglyceride (p < 0:01) levels were signiﬁcantly associated with T2DM. However, T2DM subjects
had lower cholesterol (p = 0:033) and high-density lipoprotein (p < 0:01) results when compared to their control
counterparts.
When adjusted for T. gondii IgG seropositivity, it was
found that seropositive T2DM subjects had a signiﬁcantly
lower red cell distribution width (RDW), a measure of the
variation in the size and volume of a patients red blood cells,
than seronegative individuals (average of 3.5 and 6.8, respectively; p < 0:001). A similar trend was seen in the control
group where seropositive subjects had signiﬁcantly lower
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Table 2: Univariate analysis of the variables associated with the seroprevalence of anti-T. gondii IgG antibodies among T2DM patients and
control subjects. BHS, Western Australia.
Toxoplasma serology
T2DM (n, %)
Controls (n, %)
POS
NEG
POS
NEG
Gender (IgG)
Male
51 (68.0)
Female
42 (56.0)
Total
93 (62)
Gender (IgM)
Male
5 (6.7)
Female
3 (4.0)
Total
8 (5)
Health
SOB walking
19
Chronic cough
15
Chronic phlegm
16
Rhinitis
51
Wheeze
23
Chest tightness
27
Disease state
Asthma
20
Arthritis
42
Bronchitis
17
Cancer
4
Eczema
12
Food allergies
12
Hay fever
28
Other chest
12
Pleurisy
8
Pneumonia
17
Sinusitis
21
Pet ownership
Cat ownership
13
Dog ownership
41
Other pet ownership
16
2
Body mass index (BMI, kg/m )
Underweight: <18.5
0
Normal: 18.5-24.9
11
Overweight: 25.0-29.9
40
Obese: >30.0
42
Waist
M > 102 cm, F > 88 cm
53

OR

95% CI

p value

24
33
57

53 (70.7)
46 (61.3)
99 (66)

22
29
51

0.88
0.80
0.84

0.44-1.77
0.42-1.54
0.52-1.35

0.723
0.507
0.470

70
72
142

2 (2.7)
13 (17.3)
15 (10)

73
62
145

2.61
0.20
0.51

0.49-13.88
0.05-0.73
0.21-1.23

0.246
0.008
0.129

74
78
77
42
70
66

11
20
15
46
21
19

88
79
84
53
78
80

2.05
0.76
1.16
1.40
1.22
1.72

0.92-4.59
0.36-1.59
0.54-2.51
0.79-2.47
0.62-2.39
0.88-3.37

0.076
0.465
0.699
0.275
0.562
0.110

73
51
76
89
81
81
65
81
85
76
72

20
36
22
4
10
8
26
10
7
18
19

79
63
77
95
89
91
73
89
92
81
80

1.08
1.44
0.78
1.07
1.32
1.69
1.21
1.32
1.24
1.01
1.23

0.54-2.17
0.81-2.57
0.39-1.59
0.26-4.40
0.54-3.22
0.66-4.33
0.64-2.27
0.54-3.22
0.43-3.56
0.48-2.10
0.61-2.47

0.824
0.215
0.507
0.938
0.542
0.274
0.554
0.542
0.693
0.996
0.563

80
52
77

22
37
19

77
62
80

0.57
1.32
0.87

0.27-1.21
0.74-2.35
0.42-1.82

0.140
0.344
0.721

0
10
22
24

1
30
44
24

0
20
16
15

—
0.73
0.66
1.09

—
0.26-2.05
0.66-1.43
0.48-2.48

—
0.553
0.293
0.830

32

33

16

0.8

0.38-1.68

0.561

n: number of subjects; POS: number of subjects in which anti-IgG antibodies were detected; NEG: number of subjects in which anti-IgG antibodies were not
detected; OR: odds ratio; 95% CI: 95% conﬁdence interval; SOB: shortness of breath; M: male; F: female.

RDW values than seronegative individuals (average of 3.1
and 5.8, respectively; p < 0:01). Monocyte counts were also
lower in seropositive T2DM subjects (p = 0:044) while higher
neutrophil counts were observed in seropositive control subjects (p = 0:032). The remaining anthropometric examinations and laboratory results were comparable between the

study groups and no signiﬁcant association with T. gondii
seropositivity was found (p > 0:05).
Correlation heat maps were generated to examine possible relationships between T. gondii seropositivity and the laboratory and anthropometric determinations in the control
and T2DM study groups (Figures 2 and 3, respectively).

Journal of Parasitology Research
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Figure 1: Seroprevalence of anti-T. gondii IgG antibodies among patients with T2DM and control subjects, stratiﬁed by age group. BHS,
Western Australia. Average rate of seropositivity increase was calculated at 0.97% and 0.57%, per year of age, for the T2DM and control
groups, respectively. Error bars represent standard error of the respective proportions.
Table 3: Duration of diabetes in T2DM subjects with and without T. gondii infection as determined by IgG serology. Average age of T2DM
and control subjects with and without T. gondii infection as determined by IgG serology. BHS, Western Australia.

Duration of T2DM (years)
Age of subjects (years)

Age of subjects (years)

Toxoplasma IgG serology in T2DM subjects
POS (n = 93)
NEG (n = 57)
7:6 ± 6:2
5:6 ± 4:8
63:2 ± 13:0

52:8 ± 16:1

Toxoplasma IgG serology in control subjects
POS (n = 99)
NEG (n = 51)
60:9 ± 15:0
54:5 ± 16:7

p value
0.044
<0.001

0.019

Values are shown as mean ± standard deviation. POS: number of subjects in which anti-IgG antibodies were detected; NEG: number of subjects in which
anti-IgG antibodies were not detected.

Moderate positive correlations were observed between creatinine and weight (r = 0:62, p < 0:01), body mass index (BMI,
r = 0:53, p < 0:01), waist circumference (r = 0:56, p < 0:01),
systolic blood pressure (SBP, r = 0:75, p < 0:01), hemoglobin
(Hb, r = 0:66, p < 0:01), hematocrit (Hct, r = 0:64, p < 0:01),
red cell count (RCC, r = 0:54, p < 0:05), and bilirubin
(r = 0:55, p < 0:01) in the control seronegative group but
not in the control seropositive group. However, in the control
seropositive group, creatinine correlated with red cell distribution width (RCDW, r = 0:55, p < 0:05) which was not the
case for the seropositive group (r = 0:09).
Similarly, moderate positive relationships were noted
between creatinine and height (r = 0:73, p < 0:01), Hb
(r = 0:54, p < 0:05), and Hct (r = 0:51, p < 0:01) in the
T2DM seronegative group but not in the seropositive
group. However, a strong positive association between creatinine and total protein was evident in the T2DM seropositive group (r = 0:71, p < 0:01) but not in the seronegative
group (r = 0:20). All other parameters displayed correlations of negligible magnitude between the T. gondii seropositive and seronegative groups in the T2DM and control
cohorts.

4. Discussion
Globally, few studies have been conducted to explore the
association between T. gondii infection and diabetes with
conﬂicting reported results [25–32]. Based on the ﬁndings
of the present study, T. gondii infection appears very common in both T2DM patients and healthy non-T2DM control
subjects living in Busselton, Western Australia. Our investigation showed that 62.0% of the subjects with T2DM and
66.0% of the healthy control subjects were seropositive for
anti-T. gondii IgG antibodies with no signiﬁcant diﬀerence
observed between the two groups (p = 0:84). Therefore, the
ﬁndings of the present study do not support an association
between T2DM and T. gondii infection. Similarly, an Iranian
descriptive case-control study in which 150 diabetic patients
and 150 healthy individuals were tested for anti-T. gondii IgG
antibodies using an ELISA method found that 52.6% of diabetic patients were IgG seropositive compared to 50.6% of
the healthy individuals [25]. In addition, a recent age- and
gender-matched case-control study conducted in Mexico
also found no serological evidence of an association between
T. gondii infection and diabetes mellitus [26]. The authors
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Table 4: Comparison of selected laboratory and anthropometric examinations, raw, and after adjustment for T. gondii infection status
between the T2DM (n = 150) and control groups (n = 150). BHS, Western Australia.
T2DM
IgG POS
IgG NEG

p

Control
IgG POS
IgG NEG

T2DM

Control

p

Height (cm)

168:1 ± 9:1

168:4 ± 9:3

0.787

167:7 ± 9:4

168:9 ± 8:8

0.455

167:8 ± 9:8

169:7 ± 8:2

0.234

Weight (kg)

85:0 ± 18:4

77:2 ± 15:6

<0.01

85:5 ± 17:4

84:3 ± 20:0

0.704

77:1 ± 16:1

77:3 ± 14:5

0.963

Parameter

p

30:0 ± 6:0

27:1 ± 4:5

<0.01

30:4 ± 6:1

29:4 ± 5:9

0.307

27:3 ± 4:6

26:8 ± 4:4

0.490

Waist (cm)

100:4 ± 14:8

91:3 ± 13:2

<0.01

102:0 ± 13:7

97:8 ± 16:1

0.091

92:3 ± 12:8

89:4 ± 13:9

0.197

SBP (mmHg)

128:7 ± 19:9

124:3 ± 17:6

0.043

130:5 ± 20:1

125:8 ± 19:4

0.164

126:1 ± 17:9

120:8 ± 16:5

0.080

DBP (mmHg)

79:3 ± 9:7

77:4 ± 10:3

0.111

79:7 ± 9:7

78:5 ± 9:7

0.471

78:3 ± 10:7

75:7 ± 9:5

0.140

Hb (g/L)

145:8 ± 12:7

145:4 ± 13:0

0.764

147:1 ± 12:5

143:8 ± 12:8

0.123

145:8 ± 13:2

144:5 ± 12:8

0.547

Hct (L/L)

0:4 ± 0:0

0:4 ± 0:0

0.544

0:4 ± 0:0

0:4 ± 0:0

0.122

0:4 ± 0:0

0:4 ± 0:0

0.666

RCC^

4:8 ± 0:4

4:7 ± 0:4

0.105

4:8 ± 0:4

4:8 ± 0:4

0.271

4:7 ± 0:5

4:7 ± 0:4

0.577

RDW (%)

4:8 ± 6:0

4:0 ± 5:8

0.296

3:5 ± 5:6

6:8 ± 6:2

<0.01

3:1 ± 5:4

5:8 ± 6:3

<0.01

2

BMI (kg/m )

WCC∗

6:5 ± 2:1

6:0 ± 1:6

0.016

6:3 ± 1:7

6:9 ± 2:6

0.112

6:1 ± 1:5

5:7 ± 1:7

0.086

Lymph∗ (×1012/L8)

2:0 ± 0:5

1:8 ± 0:5

0.020

2:0 ± 0:6

2:0 ± 0:7

0.864

1:9 ± 0:6

1:8 ± 0:5

0.753

Mono∗

0:5 ± 0:1

0:4 ± 0:1

0.051

0:4 ± 0:2

0:5 ± 0:1

0.044

0:4 ± 0:2

0:4 ± 0:1

0.579

Eosin∗

0:2 ± 0:01

0:2 ± 0:01

0.735

0:2 ± 0:1

0:2 ± 0:1

0.824

0:2 ± 0:1

0:2 ± 0:1

0.401

Baso∗

0:04 ± 0:03

0:04 ± 0:03

0.523

0:04 ± 0:04

0:04 ± 0:05

0.962

0:04 ± 0:03

0:03 ± 0:03

0.114

∗

Neutro

3:8 ± 1:2

3:5 ± 1:2

0.039

4:1 ± 1:9

3:6 ± 1:3

0.064

3:6 ± 1:2

3:2 ± 1:2

0.032

Platelets

246:4 ± 67:0

247:8 ± 61:7

0.849

239:2 ± 58:6

258:0 ± 77:9

0.096

244:4 ± 62:1

254:5 ± 61:0

0.348

88:8 ± 4:2

89:8 ± 3:9

0.041

89:0 ± 4:1

88:5 ± 4:3

0.448

89:7 ± 4:0

90:0 ± 3:9

0.699

MCV (fL)
TP (g/L)

74:7 ± 5:4

74:6 ± 3:8

0.833

75:0 ± 6:3

74:3 ± 3:5

0.460

74:8 ± 3:9

74:2 ± 3:5

0.413

Alb (g/L)

46:2 ± 3:4

45:7 ± 2:4

0.210

46:2 ± 3:8

46:1 ± 2:6

0.931

45:5 ± 2:6

46:3 ± 1:9

0.055

Bili (μmol/L)

9:9 ± 5:5

10:3 ± 5:4

0.587

10:1 ± 5:4

9:7 ± 5:6

0.633

10:8 ± 6:0

9:2 ± 3:7

0.087

Gluc (mmol/L)

6:8 ± 2:4

5:2 ± 0:5

<0.01

6:9 ± 2:6

6:5 ± 2:0

0.223

5:2 ± 0:5

5:1 ± 0:4

0.223

Insulin (mU/L)

13:3 ± 9:3

7:7 ± 5:4

<0.01

13:7 ± 9:3

12:6 ± 9:3

0.516

8:1 ± 6:0

6:9 ± 4:2

0.175

CRP (mg/L)

3:3 ± 4:4

2:5 ± 3:2

0.065

2:9 ± 2:9

4:0 ± 6:2

0.173

2:6 ± 2:8

2:4 ± 3:7

0.770

Chol (mmol/L)

5:2 ± 1:2

5:5 ± 1:0

0.033

5:2 ± 1:1

5:2 ± 1:2

0.923

5:5 ± 0:9

5:4 ± 1:0

0.400

HDL (mmol/L)

1:3 ± 0:4

1:6 ± 0:5

<0.01

1:3 ± 0:4

1:3 ± 0:4

0.637

1:6 ± 0:5

1:6 ± 0:5

0.898

LDL (mmol/L)

3:1 ± 1:0

3:3 ± 0:9

0.066

3:1 ± 1:0

3:0 ± 0:9

0.545

3:3 ± 0:8

3:2 ± 0:9

0.624

Trig (mmol/L)

1:8 ± 1:1

1:4 ± 0:6

<0.01

1:8 ± 0:9

1:9 ± 1:2

0.331

1:4 ± 0:7

1:3 ± 0:5

0.230

ALP (U/L)

72:8 ± 21:7

67:9 ± 21:6

0.051

75:5 ± 22:9

68:5 ± 18:9

0.055

66:8 ± 19:1

70:0 ± 25:7

0.390

ALT (U/L)

17:9 ± 2 5:0

14:0 ± 7:3

0.069

20:1 ± 30:8

14:4 ± 8:9

0.178

14:2 ± 7:8

13:7 ± 6:4

0.736

Creat (μmol/L)

77:4 ± 18:3

76:9 ± 17:4

0.883

81:1 ± 20:0

74:5 ± 16:6

0.199

77:7 ± 20:3

76:0 ± 14:6

0.766

Values are shown as mean ± standard deviation. T2DM: subjects with type 2 diabetes mellitus; n: number of subjects; +: subjects in which T. gondii IgG
antibodies were detected; -: subjects in which T. gondii IgG antibodies were not detected; BMI: body mass index; cm: centimeter; kg: kilogram; kg/m2:
kilogram force per square meter; SBP: systolic blood pressure; DBP: diastolic blood pressure; mmHg: millimeters of mercury; Hb: haemoglobin; Hct:
haematocrit; RCC: red cell count; RDW: red cell distribution width; WCC: white cell count; MCV: mean cell volume; TP: total protein; Alb: albumin; Bili:
bilirubin; Gluc: glucose; Chol: cholesterol; Trig: triglycerides; CRP: c-reactive protein; HDL: high-density lipoproteins; LDL: low-density lipoproteins; ALP:
alkaline phosphatase; ALT: alanine transaminase; Creat: creatinine. Units are recorded as absolute counts ∗ (×109 cells/mL), or ^(×1012 cells/L).

reported low IgG seroprevalence rates of 6.4% (10/156) and
3.2% (5/150) in the diabetic and healthy groups, respectively
(OR : 2:06; 95%CI : 0:69 − 6:19; p = 0:18).
In contrast, studies that support an association between
T. gondii infection and diabetes all report signiﬁcantly higher
seroprevalence rates of T. gondii infection in subjects with
diabetes when compared to the apparently healthy nondia-

betic individuals. It should be noted that all the investigations
originate from the Middle East and the majority include both
T1DM and T2DM patients in the case groups therefore preventing direct comparisons to be made with the present
study: Molan et al., Iraq (diabetic, 300/450, 66.6%; control,
68/203, 33.4%; p = 0:009) [27], Hemida, Iraq (diabetic,
96/172, 55.8%; control, 38/98, 38.8%; p < 0:01) [28]; Saki
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Figure 2: Correlation heat map with Pearson correlation coeﬃcient values displaying the interrelationships between 37 laboratory and
anthropometric parameters in control subjects with and without T. gondii infection. BHS, Western Australia.
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Figure 3: Correlation heat map with Pearson correlation coeﬃcient values displaying the interrelationships between 37 laboratory and
anthropometric parameters in T2DM subjects with and without T. gondii infection. BHS, Western Australia.

et al., Iran (diabetic, 47/110, 42.7%; control, 24/110, 21.8%;
p < 0:05) [29]; Shirabazou et al., Iran (diabetic, 55/91,
60.4%; control, 36/93, 38.0%; p < 0:001) [30]; Hemida et al.,
Egypt (T2DM, 14/37, 37.8%; control, 12/50, 24%; p = 0:04)

[31], and Gokce et al., Turkey (T2DM, 457/807, 56.6%; control, 56/250, 22.4%; p < 0:001) [32].
Recent systematic reviews and meta-analyses [22, 33, 34]
conducted to determine the possible association between T.
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gondii infection and diabetes mellitus concluded that T. gondii is a possible risk factor for diabetes and that further investigation is recommended. However, the studies included in
these meta-analyses share common fundamental weaknesses,
especially if they are to be considered reference baseline studies. Firstly, there is a lack of standardisation with regard to
the criteria used to deﬁne various parameters, especially the
diagnosis of diabetes. This includes deﬁning inclusion and
exclusion criteria consistent with the latest deﬁnitions of diabetes by the WHO. Secondly, there is no mention of having
excluded individuals with psychiatric conditions, including
personality disorders, from these studies (clinical heterogeneity). Thirdly, the studies were not comparable in their
methods of measuring T. gondii exposure, a fundamental factor that increases methodical heterogeneity. Lastly and perhaps most importantly, there is noteworthy geographical
and demographic skew in favor of the Middle East. To this
extent, it is interesting to note that the only two studies outside of the Middle East, the present study and that of
Alvarado-Esquivel et al. [26] conducted in Mexico, both
found that no signiﬁcant association between T. gondii infection and diabetes.
In the present study, domestic ownership of cats, dogs, or
other pets was not identiﬁed to be a risk factor associated
with T. gondii infection. Previous epidemiological studies
have reported similar observations [35, 36]. Although the
lack of an association of cat ownership may be surprising,
due to cats being biologically essential to the life cycle of T.
gondii as the only deﬁnitive hosts, contact with cats appears
to be a less important risk factor when compared to other
well-established risk factors such as contact with contaminated foods [25]. While data from other studies support cat
contact as a risk factor [37–39], prevention of T. gondii infection via cat exposure may be possible as cats only shed
oocysts for 1-3 periods in a lifetime. In addition, oocyst sporulation can be avoided by regular removal of cat litter [40].
Hence, the results from the current study may indicate that
Australian cat owners are looking after their cats very well
with regard to their hygiene.
Although some studies have identiﬁed some factors such
as BMI and some diseases like cancer as risk factors associated with the infection with T. gondii [10, 25, 29, 39–41],
the results of the present study did not ﬁnd any association
between the selected respiratory and chest conditions, various disease states, or anthropometric measurements and T.
gondii infection in Western Australia. With respect to the
biochemical and haematological laboratory analyses, all
parameters except red cell distribution width (RDW) were
comparable, and no signiﬁcant association with T. gondii
infection was found among the T2DM and control groups.
Signiﬁcantly higher RDW values were found in T. gondii
seronegative subjects from both the T2DM and control
groups when compared to seropositive subjects (p < 0:01).
The RDW forms part of the standard laboratory full blood
count measuring the range of variation in red blood cell volume and recently, higher values have been associated with
various disease states including various forms of cancer
[42], carotid artery atherosclerosis [43], and metabolic syndrome [44]. Moreover, Patel et al. [45] conducted a mortality
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follow-up study of 8,175 adults whose RDW values had been
previously recorded. They found that higher RDW were
strongly associated with an increased risk of death, and
RDW is a strong predictor of mortality. Further investigation
is warranted to conﬁrm our ﬁndings and to explore the causes
of lower RDW values from subjects infected with T. gondii.
The strengths of the present study include a systematic
health screening process leading to a representative study
population including appropriate adjustment for gender
and age. Lastly, the associated factors were in majority environmental factors hence speciﬁc factors like lifetime cat
exposure or lifetime undercooked meat consumption, that
were not available from the survey, should be investigated
in the future.

5. Conclusions
We conclude that T. gondii infection in Western Australia is
highly prevalent. There is no serological evidence of an association between T. gondii infection and T2DM in the studied
subjects in Busselton, Western Australia. Pet ownership,
amongst other parameters, was not identiﬁed as a risk factor
associated with T. gondii infection in T2DM and healthy subjects. Toxoplasmosis has been neglected in Australian notiﬁable disease programs; therefore, public health authorities
should focus on raising awareness of Toxoplasma infection
and introduce public health programs targeting T. gondii
transmission control. Further studies are needed to clarify
the role of T. gondii in T2DM.
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